A new way
to discover drugs

Disease affects not just one protein in a cell but thousands. Arpeggio embraces the complexity of biology by defining a drug's impact on hundreds of thousands of RNA molecules at once. This allows us to accurately predict whether a molecule could be an effective therapy. By scaling our transcriptomics platform, we're gearing up to accelerate the pace and efficiency of drug discovery and find new therapies for challenging diseases like drug-resistant cancer.

Start with RNA

Every cell in our body contains the same DNA sequence, yet heart cells are very different from liver cells. This is due to thousands of differences in how these cells generate (or transcribe) RNA. With our growing RNA dataset, Arpeggio is learning connections between RNA expression, cell type, and disease.

Learn More

Identify the RNAs specific to a disease

Many common diseases such as cancer and neurodegeneration are driven not just by dysfunction of a single gene but by the misregulation of hundreds or thousands of RNAs. At Arpeggio, we compare healthy and diseased cell states to identify RNA signatures that define disease. By identifying these RNAs we search for drugs that specifically reverse disease signatures.

Learn More

Scan thousands of drugs for those that target disease-specific RNAs

Drugs can have massive effects on a cell's RNA, but modulation of just a few important RNAs can treat or cure a disease. Identifying drugs that can precisely modulate these RNAs is a major goal of pharmaceutical drug development and our mission at Arpeggio.

Arpeggio utilizes a unique technology called nascent RNA sequencing to measure RNAs directly affected by a compound treatment. This allows us to identify the primary effect of a drug on a cell and very quickly hone in on its mechanism. With new advances in next-generation sequencing and robotics, we're scaling our nascent RNA sequencing platform to test tens of thousands of compounds at a time.

Learn patterns between what a drug looks like and what a drug does

Advancements in machine learning like Generative Adverserial Networks and normalizing flow methods can generate small molecules from even unseen transcriptional fingerprints. At Arpeggio, we’re using AI to generate lead-like molecules without a screen.

Arpeggio has built the world's largest database of nascent RNA sequences. For the first time, we are linking compound Structure-Activity Relationships with RNA fingerprints. Our database guides drug development by enabling predictions for whether a molecule will be toxic or impactful for a patient.

Learn More

We specialize in functional biology

Navigating complex biology requires input from many different assays. Our team includes world experts in functional genomics assay development and optimization.

About Arpeggio

Contact Us

Have questions? Interested in partnering with Arpeggio? Let us know.

Your message has been submitted.
We will get back to you within 24-48 hours.
Oops! Something went wrong.